Question 1

Why is levodopa combined with carbidopa in Parkinson's Disease treatment?

Accepted Answer

Carbidopa is a peripheral decarboxylase inhibitor that prevents levodopa breakdown outside the brain, allowing more medication to cross the blood-brain barrier. This combination enhances levodopa's therapeutic effect while minimizing side effects such as nausea and vomiting, improving overall treatment efficacy and tolerability.

Question 2

How do dopamine receptor agonists help manage Parkinson's Disease symptoms?

Accepted Answer

Dopamine receptor agonists like ropinirole and pramipexole directly stimulate dopamine receptors in the brain, reducing motor symptoms including tremors and stiffness. These agents have longer durations of action than levodopa, helping manage motor fluctuations and wearing off symptoms in patients on long-term treatment.

Question 3

What role do COMT inhibitors play in Parkinson's Disease pharmacotherapy?

Accepted Answer

COMT inhibitors such as tolcapone and entacapone block the enzyme that degrades levodopa, allowing higher concentrations to reach the brain. These medications enhance levodopa's therapeutic effect and reduce wearing off symptoms, improving symptom control in patients experiencing motor fluctuations.

Question 4

How do anticholinergic medications manage tremors and rigidity in Parkinson's Disease?

Accepted Answer

Anticholinergics such as benztropine and trihexyphenidyl prevent acetylcholine binding, a neurotransmitter involved in movement control. By blocking acetylcholine activity, these medications help manage tremors and rigidity, particularly in early-stage disease, though they may cause sedation and confusion in older patients.

Question 5

What are the mechanisms of action for MAO-B inhibitors in treating Parkinson's Disease?

Accepted Answer

Selective MAO-B inhibitors like selegiline and rasagiline inhibit dopamine breakdown in the brain, increasing its bioavailability and reducing motor symptoms. Unlike other monoamine oxidase inhibitors, these agents do not substantially inhibit peripheral metabolism of catecholamines, making them safer for use in Parkinson's Disease management.

Question 6

How does amantadine address motor complications in Parkinson's Disease?

Accepted Answer

Amantadine, an antiviral agent, ameliorates symptoms and dyskinesias by boosting dopamine release and blocking glutamate receptors. It is used as initial therapy for mild Parkinson's Disease and as an adjunct in patients on levodopa experiencing dose-related fluctuations and dyskinesias, with minimal side effects when properly titrated.

Question 7

What are the long-term complications of levodopa therapy in Parkinson's Disease?

Accepted Answer

Long-term levodopa use can lead to motor complications such as response fluctuations and dyskinesias. Additionally, levodopa may induce hallucinations and confusion, especially in older patients and those with preexisting cognitive dysfunction, requiring adjunctive treatments like atypical antipsychotics to manage these adverse effects.

Doença de Parkinson: Tratamento

Browse More Videos